See the latest news and media coverage for Vesalic. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotech developing ALS therapies and diagnostics
vesalic.comLast updated
In short: Vesalic emerged from stealth after discovering systemic metabolic dysfunction as a primary driver of ALS and motor neuron diseases.
The AI-based platform achieves >90% accuracy for ALS and reveals convergent lipid dysregulation patterns with Alzheimer's and Parkinson's, supported by Maastricht University's M4i collaboration.
The company announced its first major scientific finding, targeting amyotrophic lateral sclerosis.
They leverage a systemic process discovery and blood-based signature. Advances may revolutionize treatment and impact other neurodegenerative diseases.
It uses novel biomarker-based technology based on a previously unrecognized disease signature. FirstWord Pharma highlights the recent launch.
Landmark analyses from VESALIUS-CV reveal that the cardiovascular benefits of intensive LDL lowering build meaningfully over time in primary prevention—reinforcing the "lower for longer" principle...
Newco Vesalic Ltd. has formed to take forward research indicating extracellular vesicles secreted by skeletal muscle cells carry toxic payloads that are key drivers of...
Vesalic is pioneering a novel therapeutic to intercept and neutralise these toxins, potentially slowing or halting progression of monogenic and sporadic forms of ALS In...
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS...
Track Vesalic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Vesalic and other trending companies.